Clinical trial NCT07014007: Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks
Official title: Open-label Study to Assess the Tolerance and Efficacy of the Product RV4421B-EV0407, Applied in Paediatric and Adult Populations With Mild to Moderate Atopic Dermatitis for 12 Weeks
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Atopic Dermatitis
Keywords: Atopic Dermatitis
Eczema
Flare
Inflammatory skin disease
Altered skin barrier
Dryness
Itching
Redness
Stinging
Burning sensation
Lead sponsor: Pierre Fabre Dermo Cosmetique
Sponsor class: INDUSTRY
First posted: 2025-06-10
Enrollment: 105
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.

This product is already marketed in several countries. The objective of this clinical study is to evaluate the safety and efficacy of the study product when used alone or in association with topical corticosteroid therapy, in an ethnically diverse adult and pediatric population (including dark skin) and over a long period of time with a 12-week follow-up.

5 visits are planned:

* Visit 1: Inclusion visit (Day 1)
* Visit 2: Intermediate visit (Phone visit - Between Day 8 and Day 15)
* Visit 3: Intermediate visit (Day 29 ± 3 days)
* Visit 4: Intermediate visit (Day 57 ± 3 days)
* Visit 5: End of study visit (Day 85 ± 3 days)


Eligibility criteria: Inclusion criteria:

* Male or female, with any phototype according to Fitzpatrick classification aged:
* Group 1 (infants group): from 3 months to 23 months old included
* Group 2 (children group): from 24 months to 12 years old included
* Group 3 (teenagers \& adults group): from 13 years old
* Subject with a diagnosis of atopic dermatitis according to the U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis (Williams HC, Burney PG, et al.).
* Subject with studied areas (lesions and prevailing xerotic areas) limited up to 30% of the body surface area
* Subject with mild to moderate Atopic Dermatitis

Criteria related to treatments and/or products:

• Topical corticosteroids treatments (following international treatment guidelines for each age sub-group and including investigator agreement) applied on AD lesions areas since 1 to 5 days before the inclusion and ongoing at the time of inclusion. \*

\*The investigator will be authorized to adjust the treatment during the study.

Exclusion criteria:

Criteria related to the skin condition or the disease:

* Infant with Atopic Dermatitis lesions or prevailing xerotic areas located on the diaper (groups 1 \& 2)
* Subject with history of allergy or intolerance to any of the study product(s) ingredients or material used for the research
* Subject having any other dermatologic condition than Atopic Dermatitis, or characteristics (like tattoo...) on the studied areas liable to interfere with the study assessments
* Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Knowledge of Acquired Immunodeficiency Syndrome or Infectious (acute or chronic)

Criteria related to treatments and/or products:

* Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study
* Phototherapy performed within 4 weeks before the inclusion visit or planned to be started during the study
* Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study
* Systemic corticosteroids treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study
* Systemic antibiotics for dermatological purposes treatment established or modified within 2 weeks before the inclusion or ongoing or planned to be started during the study
* Systemic antihistaminic treatment established or modified within 2 weeks before the inclusion
* Topical treatments (immunomodulators (TIMs), non-steroidal anti-inflammatory, antihistaminic, antibiotics for dermatological purposes or antiseptics) applied on studied areas within 1 week before the inclusion or ongoing or planned to be started during the study
* Any other topical treatment or product applied on studied areas incompatible with the study or liable to interfere with the study assessments according to the investigator, in the weeks prior to the inclusion visit, ongoing or planned to be started during the study
* Skin care product (including moisturizer) applied on the whole body between the evening before the visit and the inclusion.
* Water and/or any cleansing product, applied on the whole body within 4 hours before the inclusion visit. If there is no studied area on the face, the subject is allowed to do a light face wash without time restriction (especially in the morning of the visit).
* Subject who plans to modify his/her usual moisturizer (allowed outside studied areas) and/or care habits during the study

Treatment of the mother if the subject of group 1 and 2 is breastfed:

* Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study
* Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or planned to be started during the study
* Systemic corticosteroids established or modified within 2 weeks before the inclusion or planned to be started during the study
* Systemic antihistaminic established or modified within 2 weeks before the inclusion
* Systemic antibiotics for dermatological purposes established or modified within 1 week before the inclusion or planned to be started during the study

Primary outcomes:
measure: Local tolerance of the product RV4421B-EV0407 on studied areas
timeFrame: Day 85
Secondary outcomes:
measure: Local tolerance of the product RV4421B-EV0407 on studied areas at several timepoints
timeFrame: Day 1, 10 to 30 minutes after the first application, Day 29 & Day 57
measure: Recording of adverse events
timeFrame: From Day 1 to Day 85
measure: Local-SCORAD (SCORing Atopic Dermatitis)
timeFrame: Day 1, Day 29, Day 57 & Day 85
measure: SCORAD (SCORing Atopic Dermatitis)
timeFrame: Day 1, Day 29, Day 57 & Day 85
measure: IGA (Investigator's Global Assessment)
timeFrame: Day 1, Day 29, Day 57 & Day 85
measure: PO-SCORAD (Patient Oriented SCORing Atopic Dermatitis)
timeFrame: Every 2 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 1 to Day 85
measure: SGA (Subject's Global Assessment)
timeFrame: Every 2 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 15 to Day 85
measure: Subject quality of life DLQI for subjects from 16 years
timeFrame: Every 4 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 29 to Day 85
measure: Subject quality of life CDLQI for subjects from 4 years to 15 years included
timeFrame: Every 4 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 29 to Day 85
measure: Subject quality of life IDQOL for subjects from 3 months to 3 years included
timeFrame: Every 4 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 29 to Day 85
measure: Subject's satisfaction questionnaire
timeFrame: at Day 1 (10 to 30 minutes after the 1st product application), within 2 days before Day 29 or at Day 29 (± 3 days), within 2 days before Day 85 or at Day 85 (± 3 days)
Other outcomes:
Locations:
Study officials:
References: